Table 3.

Clinical characteristics of patients presenting with paraneoplastic neurological syndromes and responses to treatment, clinical course, and mean-elapsed time between neurological manifestation and the diagnosis of a tumor.

Patient	Syndrome	Antibody	Therapy	Response to Therapy	Course	Time to Tumor Diagnosis
1	Myasthenia gravis	AchR, Ti	Prednisone p.o., Pyridostigmine, Surgery	Improvement	Monophasic	3 months
2	Limbic encephalitis	Ma2	Antiepileptic drug (lacosamide), Surgery	Improvement in narcolepsy, minor problems in memory	Monophasic	2 years
3	Limbic encephalitis	ΙgLON5	Prednisolone i.v.	Stable	Monophasic	1 year
4	LEMS	P/Q-VGCC	IVIg, Pyridostigmine, Chemotherapy, Surgery	Improvement	Monophasic	1 year
5	Myasthenia gravis	AchR	Prednisone p.o., Surgery, radiotherapy	Improvement	Monophasic	1 month
6	LEMS, Limbic encephalitis	Hu, P/Q-VGCC	Prednisone p.o., Chemotherapy	Stable	Monophasic	1 week
7	Cerebellar Ataxia	Yo	IVIg, prednisolone i.v., surgery	Improvement	Death	1 month
8	LEMS	Hu, P/Q-VGCC	IVIg, amifampridine, surgery	Improvement	Monophasic	2 months
9	Peripheral neuropathy	Hu	IVIg, chemotherapy	Worsening	Death	2 weeks
10	Limbic encephalitis	GAD65	Prednisone p.o., antiepileptic drug (lacosamide)	Improvement in 1st year with gradual worsening in behavioral disorder and epileptic seizures	Relapsing	20 days
11	Myasthenia gravis	AchR	Plasmapheresis, IVIg, Prednisone p.o., cyclophosphamide, mycophenolate mofetil, surgery	Improvement	Relapsing	3 months
12	Myasthenia gravis	AchR	IVIg, Prednisone p.o., Surgery	Improvement	Monophasic	1 month
13	Cerebellar Ataxia	Yo	Prednisolone i.v.	Stable	Monophasic	1 year

Abbreviations: AchR = muscle-type acetylcholine receptor binding antibodies; Ti = titin; GAD = glutamic acid decarboxylase; P/Q-VGCC = P/Q type voltage-gated calcium channel (VGCC) antibodies; LEMS = Lambert–Eaton myasthenic syndrome; p.o. = per os; i.v. = intravenous; IVIg = intravenous immunoglobulins.